NCT03286842: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have germline (inherited) or somatic BRCA1/2 mutations
Exclusions: Symptomatic uncontrolled brain metastases- see trial for details

Comments are closed.

Up ↑